These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30589629)

  • 1. External Validation of a COPD Risk Measure in a Commercial and Medicare Population: The COPD Treatment Ratio.
    Stanford RH; Lau MS; Li Y; Stemkowski S
    J Manag Care Spec Pharm; 2019 Jan; 25(1):58-69. PubMed ID: 30589629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a drug adherence index for COPD.
    Bengtson LGS; Bancroft T; Schilling C; Buikema AR; Stanford RH
    J Manag Care Spec Pharm; 2021 Feb; 27(2):198-209. PubMed ID: 33506734
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.
    Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Vekeman F; Gauthier-Loiselle M; Duh MS; Merrigan JF; Schatz M
    Ann Am Thorac Soc; 2016 Jul; 13(7):1067-75. PubMed ID: 27070274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study.
    Lane DC; Stemkowski S; Stanford RH; Tao Z
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1165-1172. PubMed ID: 30362922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission.
    Tran M; Xiang P; Rascati KL; Stock EM; Godley PJ; Coleman A; Bogart MR; Stanford RH
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1186-93. PubMed ID: 27668567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COPD treatment ratio: a measure for improving COPD population health.
    Parikh MA; Burbage SC; Gabriel MH; Shirley BE; Campbell PJ
    Am J Manag Care; 2024 Sep; 30(9):e251-e257. PubMed ID: 39302258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
    Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation and Assessment of the COPD Treatment Ratio as a Predictor of Severe Exacerbations.
    Stanford RH; Korrer S; Brekke L; Reinsch T; Bengtson LGS
    Chronic Obstr Pulm Dis; 2020 Jan; 7(1):38-48. PubMed ID: 31999901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claims-based risk model for first severe COPD exacerbation.
    Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Schatz M; Vekeman F; Gauthier-Loiselle M; Merrigan JFP; Duh MS
    Am J Manag Care; 2018 Feb; 24(2):e45-e53. PubMed ID: 29461849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
    Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
    Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
    Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population.
    Sethi S; Make BJ; Robinson SB; Kumar S; Pollack M; Moretz C; Dreyfus J; Xi A; Powell D; Feigler N
    Int J Chron Obstruct Pulmon Dis; 2022; 17():593-608. PubMed ID: 35342290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [No Abstract]   [Full Text] [Related]  

  • 17. COPD exacerbations associated with the modified Medical Research Council scale and COPD assessment test among Humana Medicare members.
    Pasquale MK; Xu Y; Baker CL; Zou KH; Teeter JG; Renda AM; Davis CC; Lee TC; Bobula J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():111-21. PubMed ID: 26834468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a predictive model to identify patients at risk of severe COPD exacerbations using administrative claims data.
    Annavarapu S; Goldfarb S; Gelb M; Moretz C; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2121-2130. PubMed ID: 30022818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.
    Abudagga A; Sun SX; Tan H; Solem CT
    Int J Chron Obstruct Pulmon Dis; 2013; 8():175-85. PubMed ID: 23589684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.